Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …

CD8+ T cells are critical for elimination of cancer cells. Factors within the tumor
microenvironment (TME) can drive these cells to a hypofunctional state known as …

Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19
chimeric antigen receptor (CAR19) T cells relapse. To characterize determinants of …

Cytotoxic T lymphocytes (CTLs) are antigen-specific killer cells equipped to identify and
eliminate host cells that have been altered through infection or transformation. Both chimeric …

Acquired resistance to immunotherapy remains a critical yet incompletely understood
biological mechanism. Here, using a mouse model of pancreatic ductal adenocarcinoma …

Generating stem-like memory T cells (TSCM) is a potential strategy to improve adoptive
immunotherapy. Elucidating optimal ways to modulate signaling pathways that enrich TSCM …

Background Commercial anti-CD19 chimeric antigen receptor T-cell therapies (CART19)
are efficacious against advanced B-cell non-Hodgkin lymphoma (NHL); however, most …

Immunotherapy has revolutionized the treatment of cancer. In particular, immune checkpoint
blockade, bispecific antibodies, and adoptive T-cell transfer have yielded unprecedented …

The development of chimeric antigen receptor T cells (CAR-T cells) has marked a new era in
cancer immunotherapy. Based on a multitude of durable complete remissions in patients …

The efficacy of T cell-based immunotherapies is limited by immunosuppressive pressures in
the tumor microenvironment. Here we show a predominant role for the interaction between …